BioInvent International : announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab) -April 02, 2024 at 09:08 am EDT

English


Swedish









...

Related Keywords

United States ,Sweden ,Cecilia Hofvander ,Martin Welschof ,International Business Gmb ,Bioinvent International Ab Nasdaq Stockholm ,Bioinvent International ,Merck Sharp Dohme ,Merck Co Inc ,Twitter ,Invent International ,Nasdaq Stockholm ,Business Gmbh ,Merck Sharp ,Senior Director Investor ,Markets ,